Use of cyclosporin in the treatment of steroid resistant post-keratoplasty atopic sclerokeratitis

11Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

Aims - To demonstrate that oral cyclosporin is successful in the management of steroid refractory post-keratoplasty atopic sclerokeratitis (PKAS). Methods - Series of three patients. Results - The patients developed PKAS between 2 and 11 days after surgery. All cases failed to respond to oral prednisolone 60-80 mg daily for 10-30 days but resolved with the addition of systemic cyclosporin 5.0-7.5 mg/kg/day. There have been no relapses following withdrawal of therapy after 3-18 months. Conclusions - PKAS is an uncommon, but severe, complication of corneal graft surgery and often responds to oral prednisolone treatment. Oral cyclosporin results in rapid resolution of PKAS in steroid unresponsive cases.

Cite

CITATION STYLE

APA

Daniell, M. D., Dart, J. K. G., & Lightman, S. (2001). Use of cyclosporin in the treatment of steroid resistant post-keratoplasty atopic sclerokeratitis. British Journal of Ophthalmology, 85(1), 91–92. https://doi.org/10.1136/bjo.85.1.91

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free